Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 276 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it contrast to its rivals? We will compare Fresh Tracks Therapeutics to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.
Volatility and Risk
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Get
Fresh Tracks Therapeutics alerts:
Profitability
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.07% | -37.03% |
Insider and Institutional Ownership
7.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 46.7% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all "Biological products, except diagnostic" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Fresh Tracks Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 873 | 3827 | 10681 | 159 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 133.90%. As a group, "Biological products, except diagnostic" companies have a potential upside of 81.42%. Given Fresh Tracks Therapeutics' higher possible upside, equities research analysts plainly believe Fresh Tracks Therapeutics is more favorable than its rivals.
Valuation and Earnings
This table compares Fresh Tracks Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.20 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -1.75 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 7 of the 10 factors compared.
About Fresh Tracks Therapeutics
(Get Rating)
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
